Anmelden Kostenlos registrieren

Inhibrx leerverkaufte Aktien zu allen Aktien

Was ist das leerverkaufte Aktien zu allen Aktien von Inhibrx?

leerverkaufte Aktien zu allen Aktien von Inhibrx, Inc. ist 9.24

Was ist die Definition von leerverkaufte Aktien zu allen Aktien?



Das Leerverkauf-Verhältnis ist die Anzahl der leervekauften Aktien geteilt durch das durchschnittliche tägliche Volumen.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

leerverkaufte Aktien zu allen Aktien von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx

Was macht Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Unternehmen mit leerverkaufte aktien zu allen aktien ähnlich Inhibrx